skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Treatment of diabetic vasculopathy: an overview

Review

(664) Views  (222) Full article downloads

Authors: Rahman S, Majumder MAA, Rahman ARA

Published Date December 2011 Volume 2011:1 Pages 21 - 36
DOI: http://dx.doi.org/10.2147/RRED.S17512

Sayeeda Rahman1, Md Anwarul Azim Majumder1, Abdul Rashid Abdul Rahman2
1Department of Clinical Sciences, School of Medical Sciences, University of Bradford, Bradford, UK; 2Cyberjaya University College of Medical Sciences, Cyberjaya, Malaysia

Abstract: Type 2 diabetes is a chronic, degenerative, and noncommunicable disease, and is associated with a high prevalence of cardiovascular morbidity and mortality. The complications of diabetic vasculopathy are commonly grouped into microvascular and macrovascular complications. In diabetes, macrovascular complications are the commonest cause of morbidity and mortality and are responsible for a high incidence of vascular diseases. The aim of this review to provide an overview of current treatment modalities for diabetic vasculopathy and highlight the importance of effective control of blood glucose, blood lipids, and blood pressure, as well as reduction of blood hypercoagulability, in lowering the macrovascular complications of diabetic vasculopathy. A literature review was conducted to retrieve the relevant information using the PubMed, Science Direct, and Google Scholar databases, reports, and books. People with type 2 diabetes are at markedly increased risk for cardiovascular disease and mortality. The initiators of vasculopathy that ultimately develop into long-term diabetic complications can be avoided by a healthy lifestyle and pharmacological intervention. Clinical trials have shown that effective control of blood glucose, blood lipids, blood pressure, and blood hypercoagulability can reduce macrovascular complications in patients with type 2 diabetes. Type 2 diabetes is responsible for premature mortality, predominantly through atherosclerotic vascular disease. Lifestyle modification and pharmacotherapy should be used to prevent or delay development of type 2 diabetes, including adverse cardiovascular outcomes. A multidisciplinary approach involving patients, health professionals, and diabetic educators should be used to combat the type 2 diabetes epidemic and its associated cardiovascular complications.

Keywords: type 2 diabetes, diabetic vasculopathy, macrovasculopathy, cardiovascular disease





 

Other articles by Dr Sayeeda Rahman



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Effect of protease inhibitors (indinavir and ritonavir) on the pharmacokinetics of gliclazide in rabbits
Diuretics as pathogenetic treatment for heart failure
Predicting response to incretin-based therapy
A systematic review of the individual determinants of research evidence use in allied health
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Primary care for diabetes mellitus: perspective from older patients